Tenet Healthcare Corporation announced yesterday that it has completed the sale of three of its hospitals in South Carolina to Novant Health for approximately $2.4 billion. It has also entered into a definitive agreement with UCI Health for the sale of four Tenet hospitals and related operations in Orange County and Los Angeles County, California […]
While Medicare Advantage remains attractive to the healthcare industry due to strong growth, high revenue and earnings per member, profitability is on the decline, according to a new analysis by Moody’s Investor Service.
Sickle cell disease (SCD) will be the initial focus of the Centers for Medicare and Medicaid Services Cell and Gene Therapy (CGT) Access Model, which was initially announced in February 2023.
Artificial intelligence is on the rise in healthcare, and both in-house and third-party solutions are beginning to creep their way into the market. But the monitoring of health, and the real-world impact of these AI products, is often overlooked after deployment. Many AI products lack rigorous monitoring, posing risks to patients and operations.
Dr. Jared Saul, Amazon Web Services chief medical officer, talks about the benefits of artificial intelligence and machine learning, but also AWS’ concerns about their use in healthcare.
Medicare Advantage payments are expected to increase on average by 3.7%, or over $16 billion, from 2024 to 2025, as proposed, from the Centers for Medicare and Medicaid Services.
HCA Healthcare plans on making $5 billion in capital investments this year, with a large concentration in outpatient facilities.
Health company Cigna has entered into a definitive agreement to sell its Medicare Advantage, Supplemental Benefits, Medicare Part D and CareAllies businesses to Health Care Service Corporation (HCSC) for about $3.7 billion.
Ten months after states began the redetermination process, an estimated 16 million beneficiaries have lost Medicaid coverage, according to KFF analysis.
The Food and Drug Administration has set March 8 as the end of its emergency use authorization (EUA) for Paxlovid for adult patients, the agency has said this week. The medication is given to those considered high risk for progression to severe COVID-19, including hospitalization or death.